Lundbeck and partner present "slam-dunk" data for new Alzheimer's drug
Analysts are excited about Lundbeck’s final data presentation for Rexulti, which has reached all endpoints in a phase III study.
by christian bundgaard, translated by catherine brett
The new data that Lundbeck and Otsuka have released on their Alzheimer’s candidate Rexulti has eliminated any doubt about the treatment’s potential, Danish financial daily Børsen writes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck CFO begins work
For subscribers
Lundbeck Foundation makes hire for new investment department
For subscribers
